The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
Alexander M. Eggermont
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Vanna Chiarion-Sileni
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Jean Jacques Grob
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche
Reinhard Dummer
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Henrik Schmidt
Honoraria - Bristol-Myers Squibb
Omid Hamid
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Caroline Robert
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Ventana
Jon M. Richards
Stock Ownership - Bristol-Myers Squibb (I)
Celeste Lebbe
Honoraria - Bristol-Myers Squibb
Virginia Ferraresi
No relevant relationships to disclose
Michael Smylie
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Cyril Konto
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ravichandra Karra Gurunath
No relevant relationships to disclose
Veerle de Pril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Stefan Suciu
No relevant relationships to disclose
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb